Emerging drugs to treat Crohn’s disease

Bibliography

• PODOLSKY DK: Inflammatory bowel disease. N. Engl. J. Med. (2002) 347:417-429.
   PubMed Web of Science ®Google Scholar
• HUGOT JP, CHAMAILLARD M, ZOUALI H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature (2001) 411:599-603.
   PubMed Web of Science ®Google Scholar
• OGURA Y, BONEN DK, INOHARA N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature (2001) 411:603-606.
   PubMed Web of Science ®Google Scholar
• FRANCHIMONT D, VERMEIRE S, EL HOUSNI H et al.: Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut (2004) 53:987-992.
   PubMed Web of Science ®Google Scholar
• WEHKAMP J, FELLERMANN K, HERRLINGER KR et al.: Mechanisms of disease: defensins in gastrointestinal diseases. Nat. Clin. Pract. Gastroenterol. Hepatol. (2005) 2:406-415.
   PubMedGoogle Scholar
• MUNKHOLM P, LANGHOLZ E, DAVIDSEN M, BINDER V: Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut (1994) 35:360-362.
   PubMed Web of Science ®Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. (1997) 337:1029-1035.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (2002) 359:1541-1549.
   PubMed Web of Science ®Google Scholar
• PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med. (1999) 340:1398-1405.
   PubMed Web of Science ®Google Scholar
• SANDS BE, ANDERSON FH, BERNSTEIN CN et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med. (2004) 350(9):876-885.
   PubMed Web of Science ®Google Scholar
• BAERT F, NOMAN M, VERMEIRE S et al.:. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. (2003) 348:601-608.
   PubMed Web of Science ®Google Scholar
• FARRELL RJ, ALSAHLI M, JEEN YT et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology (2003) 124:917-924.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, PAINTEAUD G, D’HAENS G et al.: Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn’s disease but may improve pharmacokinetics. Gastroenterology (2006) 130:A-142.
   Web of Science ®Google Scholar
• SIEMANOWSKI B, KIP K, PLEVY S, REGUEIRO M: Adjustment in infliximab dose or dosing interval in Crohn’s disease. Experience from the University of Pittsburgh. Gastroenterology (2006) 130:A-142.
   Web of Science ®Google Scholar
• PACAULT V, BEN HRIZ F, GORNET JM et al.: Long term follow up of Crohn’s disease patients treated with infliximab using an episodic strategy. Gastroenterology (2006) 130:A-655.
   Google Scholar
• RUTGEERTS P, DIAMOND RH, BALA M et al.: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest. Endosc. (2006) 63(3):433-442.
   PubMed Web of Science ®Google Scholar
• VON ADRIAN UH, MACKAY CR: T-cell function and migration. N. Engl. J. Med. (2002) 343:1020-1034.
   Web of Science ®Google Scholar
• KUNKEL EJ, RAMOS CL, STEEBER DA et al.: The roles of L-selectin, β7 integrins and P-selectin in leukocyte rolling and adhesion in high endothelial venules of Peyer’s patches. J. Immunol. (1998) 161:2449-2456.
   PubMed Web of Science ®Google Scholar
• BRISKIN M, WINSOR-HINES D, SHYJAN A et al.: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. (1997) 151:97-110.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, COLOMBEL JF, ENNS R et al.: Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. (2005) 353(18):1912-1925.
   PubMed Web of Science ®Google Scholar
• MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2003) 348:15-23.
   PubMed Web of Science ®Google Scholar
• YOUDIM A, VASILIAUSKAS EA, TARGAN SR et al.: A pilot study of adalimumab in infliximab-allergic patients. Inflamm. Bowel Dis. (2004) 10:333-338.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER S, LOFTUS EV Jr et al.: Open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am. J. Gastroenterol. (2004) 99(10):1984-1989.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, SANDBORN WB, RUTGEERTS P et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-1 trial. Gastroenterology (2006) 130:323-333.
   PubMed Web of Science ®Google Scholar
• COLOMBEL J, SANDBORN WJ, RUTGEERTS P et al.: Adalimumab induces and maintains clinical response and remission in patients with active Crohn’s disease: the results of the CHARM trial. Programs and abstracts of the Digestive Disease Week, 20 – 25 May 2006, Los Angeles, CA, USA (686d).
   Google Scholar
• SHEN C, VAN ASSCHE G, RUTGEERTS P, CEUPPENS JL: Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm. Bowel Dis. (2006) 12:22-28.
   PubMed Web of Science ®Google Scholar
• SHEN C, VAN ASSCHE G, COLPAERT S et al.: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. (2005) 21:251-258.
   PubMed Web of Science ®Google Scholar
• HWANG WYK, FOOTE J: Immunogenicity of engineered antibodies. Methods (2005) 36:3-10.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, RUTGEERTS P, FEDORAK RN et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology (2005) 129(3):807-818.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, FEAGAN BG, STOINOV S et al.: Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26 week placebo-controlled Phase III study (PRECiSe 1). Gastroenterology (2006) 130:A-107.
   Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121:1088-1094.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, SANDBORN WJ, FEDORAK RN et al.: Onercept for moderate-to-severe Crohn’s disease: a randomized, doubl-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. (2006) 4:888-893.
   PubMed Web of Science ®Google Scholar
• TRAVIS SP, YAP L et al.: RDP58 – a novel and effective oral therapy for ulcerative colitis (UC) results of parallel prospective, multicentre, blinded placebo-controlled trials. Gut (2003) 52(SVI):A5.
   PubMed Web of Science ®Google Scholar
• HOMMES D, VAN DEN BLINK B, PLASSE T et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology (2002) 122:7-14.
   PubMed Web of Science ®Google Scholar
• KLEINSCHMIDT-DEMASTERS BK, TYLER KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β1a for multiple sclerosis. N. Engl. J. Med. (2005) 353:369-374.
   PubMed Web of Science ®Google Scholar
• LANGER-GOULD A, ATLAS SW, GREEN AJ et al.: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. (2005) 353:375-381.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. (2005) 353:362-368.
   PubMed Web of Science ®Google Scholar
• YOUSRY TA, MAJOR EO, RYSCHKEWITSCH C et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopahty. N Engl. J. Med. (2006) 354:924-933.
   PubMed Web of Science ®Google Scholar
• MANNON P, FUSS I, MAYER L et al.: Anti-interleukin-12 antibody for active Crohn’s disease. N. Engl. J. Med. (2004) 352:2069-2079.
   Web of Science ®Google Scholar
• HOMMES DW, MIKHAJLOVA TL, STOINOV S et al.: Fontolizumab, a humanised anti-interferon-γ antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn’s disease. Gut (2006) 55:1138-1144.
   PubMed Web of Science ®Google Scholar
• REINISCH W, HOMMES DW, VAN ASSCHE G et al.: A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-γ antibody, in patients with moderate-to-severe Crohn’s disease. Gut (2006) 55:1131-1137.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR, DIECKGRAEFE BK, VALENTINE JF et al.: Sargramostim for active Crohn’s disease. N. Engl. J. Med. (2005) 352:2193-201.
   PubMed Web of Science ®Google Scholar
• ITO H, TAKAZOE M, FUKUDA Y et al.: A pilot randomized trial of a human anti-interleukin-6 monoclonal antibody in active Crohn’s disease. Gastroenterology (2004) 126:989-996.
   PubMed Web of Science ®Google Scholar
• HOMMES D, BAERT F, VAN ASSCHE G et al.: The ideal management of Crohn’s disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology (2006) 130:A108 (Abstract).
   Google Scholar
• TEN HOVE T, VAN MONTFRANS C, PEPPELENBOSCH MP, VAN DEVENTER SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut (2002) 50:206-211.
   PubMed Web of Science ®Google Scholar
• VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology (2003) 124:1774-1785.
   PubMed Web of Science ®Google Scholar
• LUGERING A, SCHMIDT M, LUGERING N et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology (2001) 121:1145-1157.
   PubMed Web of Science ®Google Scholar
• DI SABATINO A, CICCOCIOPPO R, CINQUE B et al.: Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut (2004) 53:70-77.
   PubMed Web of Science ®Google Scholar
• RINGHEANU M, DAUM F, MARKOWITZ J et al.: Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease. Inflamm. Bowel Dis. (2004) 10:801-810.
   PubMed Web of Science ®Google Scholar
• HLAVATY T, PIERIK M, HENCKAERTS L et al.: Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment. Pharmacol. Ther. (2005) 22(7):613-626.
   PubMed Web of Science ®Google Scholar
• LICHTENSTEIN GR, FEAGAN BG, COHEN RD et al.: Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin. Gastroenterol. Hepatol. (2006) 4:621-630.
   PubMed Web of Science ®Google Scholar